Belliveau J F, Posner M R, Ferrari L, Crabtree G W, Cummings F J, Wiemann M C, O'Leary G P, Griffin H, Phaneuf M A, O'Rourke A
Cancer Treat Rep. 1986 Oct;70(10):1215-7.
Total and filterable platinum in plasma were monitored for seven courses (five patients, 25 mg/m2/day) using continuous 5-day infusions and one 30-minute infusion at a similar dose level (120 mg/m2). Maximum filterable (non-protein-bound) platinum levels (0.1-0.3 mg/L) for the extended infusions were ten to 40 times lower than that for the short-term infusion (4.0 mg/L). Filterable drug exposure as measured by the area under the [Pt]filterable-time curve is greater for the extended infusions (9.6 mg X hr/L) than that for the short-term infusion (4.8 mg X hr/L). Renal excretion of cisplatin (% of dose excreted/24-hour period after the beginning of the infusion) was measured for four courses of continuous 5-day infusions and for the 30-minute infusion. Urine excretion rates were lower for the continuous infusion (5%-8% of dose/24-hour period during the infusion) compared to the short-term infusion (33% of dose/24-hour period after the beginning of the 30-minute infusion).
采用持续5天输注以及在相似剂量水平（120mg/m²）下进行一次30分钟输注的方式，对7个疗程（5例患者，25mg/m²/天）的血浆总铂和可滤过铂进行监测。延长输注时的最大可滤过（非蛋白结合）铂水平（0.1 - 0.3mg/L）比短期输注时的水平（4.0mg/L）低10至40倍。通过[Pt]可滤过 - 时间曲线下面积测量的可滤过药物暴露量，延长输注（9.6mg·hr/L）比短期输注（4.8mg·hr/L）更高。对4个持续5天输注疗程以及30分钟输注疗程的顺铂肾排泄情况（输注开始后24小时内排泄剂量的百分比）进行了测量。与短期输注（30分钟输注开始后24小时内剂量的33%）相比，持续输注的尿排泄率较低（输注期间24小时内剂量的5% - 8%）。
